The cancer tissue page shows antibody staining in 20 different cancers. The overall cancer tissue staining statistics shows the fraction of patient samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right), using all the available antibodies to the protein targets encoded by this gene. The assay and annotation is described here.
The cancers can be ordered histologically or alphabetically.
For each cancer, the staining for each available antibody is reported as the fraction of samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right). The lenght of the bar represents the number of patient samples analysed (max=12 patients). By clicking on a cancer tissue, the detailed staining data for that cancer is available, including annotated images.
At the bottom of this page, a summary for the cancer staining for each antibody is given, together with the immunohistochemistry validation score for that antibody.
Several cases of squamous cell carcinomas, urothelial and pancreatic cancers showed moderate to strong staining. All thyroid cancers and several cases of breast cancers and malignant gliomas displayed moderate positivity. Remaining malignant cells generally displayed weak nuclear staining or were negative.
Most cancers showed moderate nuclear immunoreactivity. A few colorectal, breast and testicular cancers were strong stained. Strong membranous and nuclear positivity was observed in a few pancreatic cancers and cholangiocarcinomas. Malignant gliomas, melanomas, thyroid and renal cancers along with several malignant carcinoids and hepatocellular carcinomas were negative.
Validation
Two (or more) antibodies yielding similar or partly similar staining patterns and there is no available gene/protein characterization data
Two (or more) antibodies yielding similar or partly similar staining patterns and there is no available gene/protein characterization data
